Verona Pharma plc
VRNA
Classifica tra le azioni
#2232
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Prezzo delle azioni
$106.91
Ultima sincronizzazione: 2025-10-07
Capitalizzazione di mercato
$9.09B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
GB
Scambia Verona Pharma plc (VRNA)
Categoria
Healthcare
Margine operativo per Verona Pharma plc (VRNA)
Margine operativo al October 2026 TTM: -365.73%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Verona Pharma plc, il margine operativo attuale (TTM) è -365.73%. Alla fine del 2023, il margine operativo era 0.00%.
Storico del margine operativo per Verona Pharma plc da 2005 a 2026
Margine operativo alla fine di ogni anno
| Anno | Margine Operativo | Cambia |
|---|---|---|
| 2026 (TTM) | -365.73% | 0.00% |
| 2024 | -365.73% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | -14,435.81% | 7,776.37% |
| 2021 | -183.28% | 0.00% |
| 2020 | 0.00% | -100.00% |
| 2019 | -2,291,221.96% | 96.36% |
| 2018 | -1,166,819.68% | 53,319.21% |
| 2017 | -2,184.27% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | 0.00% |
| 2006 | 0.00% | 0.00% |
| 2005 | 0.00% | 0.00% |
Margine operativo per aziende simili o concorrenti
| Azienda | Margine Operativo | Differenza del margine operativo | Il paese |
|---|---|---|---|
| 38.59% | -100.11% |
US
|
|
| -149.01% | -99.59% |
US
|
|
| 25.57% | -100.07% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.08% |
NL
|
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.